Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma
30 nov. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in...
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
08 nov. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting
04 nov. 2021 06h00 HE
|
Talaris Therapeutics, Inc.
First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with...
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction
29 oct. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of...
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
28 oct. 2021 16h36 HE
|
Talaris Therapeutics, Inc.
Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipientsPoster with additional data from Phase 2 study follow-up to be presented at...
Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
02 sept. 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
12 août 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
14 juin 2021 16h01 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
03 juin 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...